GlassScriptPhysician profile
Benjamin H Sell
NPI 1144782293
$3,777.47
in general payments reported to CMS, 2019-2025
32 companies · $537 in 2025
The $537 reported for 2025 was more than what 81% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $1,382 · 2023: $667 · 2024: $717 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.15 |
| Education | $309.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $811.82 | 2021-2024 | |
| Abbvie INC. | $480.63 | 2021-2024 | |
| Pfizer INC. | $382.39 | 2022-2025 | |
| Lilly USA, LLC | $283.71 | 2021-2023 | Taltz |
| Organogenesis INC. | $281.49 | 2021-2022 | |
| Incyte Corporation | $248.91 | 2022-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $159.98 | 2021 | |
| Nevro Corp. | $156.10 | 2024 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.07 | 2022 | |
| Journey Medical Corporation | $81.32 | 2022 | |
| Ferring Pharmaceuticals INC. | $64.66 | 2025 | Adstiladrin |
| Pacira Pharmaceuticals Incorporated | $62.43 | 2021 | |
| Medtronic, INC. | $60.58 | 2024-2025 | Anteralign Spinal System With Titan Nanolock Surface Technology, Inceptiv |
| Novartis Pharmaceuticals Corporation | $60.23 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $59.05 | 2025 | Provenge |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.40 | 2022-2023 | Spevigo |
| Ucb, INC. | $44.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.66 | 2025 | |
| Nalu Medical, INC. | $36.53 | 2024 | Nalu Neurostimulation System |
| Blue Earth Diagnostics | $35.47 | 2025 | Posluma |
| Merck Sharp & Dohme LLC | $31.86 | 2025 | Keytruda |
| Progenics Pharmaceuticals, INC. | $28.26 | 2025 | |
| Sumitomo Pharma America, INC. | $26.91 | 2025 | Gemtesa |
| Relievant Medsystems, INC. | $26.69 | 2023 | Intracept |
| Vertos Medical, INC. | $26.47 | 2024 | Mild Device Kit |
| E.R. Squibb & Sons, L.L.C. | $24.58 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.12 | 2022 | |
| Endo USA, INC. | $23.74 | 2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $23.21 | 2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2025 | |
| Biofrontera INC. | $19.61 | 2021 | |
| Innovation Technologies INC | $19.16 | 2024 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Sell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.